PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Disease
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, will collaborate with Sheffield Hallam University in the field of epigenetics. The partnership will focus on ‘gene-based environmental biomarkers’ – epigenetic markers – for calculating risk scores for Alzheimer’s diseases. Together with PharmaKure’s blood-based biomarker, ALZmetrix https://bitly.ws/3eZTQ, this […]
